tetano
Editor, Senior Moderator
Infect Dis Ther
. 2024 Jan 9.
doi: 10.1007/s40121-023-00900-3. Online ahead of print. Remdesivir for the Treatment of COVID-19: A Narrative Review
Patrick O Godwin[SUP] 1 [/SUP], Bryan Polsonetti[SUP] 2 [/SUP], Michael F Caron[SUP] 2 [/SUP], Thomas F Oppelt[SUP] 3 [/SUP]
Affiliations
Despite the wide availability of effective vaccines, COVID-19 continues to be an infectious disease of global importance. Remdesivir is a broad-spectrum antiviral and was the first US Food and Drug Administration-approved treatment for COVID-19. In clinical guidelines, remdesivir is currently the only recommended antiviral for use in hospitalized patients with COVID-19, with or without a supplemental oxygen requirement. It is also recommended for nonhospitalized patients with COVID-19 and hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are at high risk of progression to severe disease. This narrative review explores the evidence for remdesivir across various clinical outcomes and evolution of clinical guidelines through a survey over time of randomized controlled trials, observational studies, and meta-analyses. Remdesivir, compared to standard of care, appears to improve survival and disease progression in a variety of patient populations with COVID-19 across a spectrum of disease severity and SARS-CoV-2 variant periods. Remdesivir also appears to improve time to clinical recovery, increase rate of recovery, and reduce time on supplemental oxygen and readmission rates. More recent large, real-world studies further support the early use of remdesivir in a range of patient populations, including those with immunocompromising conditions.
Keywords: Antiviral therapy; COVID-19; Clinical practice guidelines; Real-world evidence; Remdesivir; SARS-CoV-2.
. 2024 Jan 9.
doi: 10.1007/s40121-023-00900-3. Online ahead of print. Remdesivir for the Treatment of COVID-19: A Narrative Review
Patrick O Godwin[SUP] 1 [/SUP], Bryan Polsonetti[SUP] 2 [/SUP], Michael F Caron[SUP] 2 [/SUP], Thomas F Oppelt[SUP] 3 [/SUP]
Affiliations
- PMID: 38193988
- DOI: 10.1007/s40121-023-00900-3
Despite the wide availability of effective vaccines, COVID-19 continues to be an infectious disease of global importance. Remdesivir is a broad-spectrum antiviral and was the first US Food and Drug Administration-approved treatment for COVID-19. In clinical guidelines, remdesivir is currently the only recommended antiviral for use in hospitalized patients with COVID-19, with or without a supplemental oxygen requirement. It is also recommended for nonhospitalized patients with COVID-19 and hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who are at high risk of progression to severe disease. This narrative review explores the evidence for remdesivir across various clinical outcomes and evolution of clinical guidelines through a survey over time of randomized controlled trials, observational studies, and meta-analyses. Remdesivir, compared to standard of care, appears to improve survival and disease progression in a variety of patient populations with COVID-19 across a spectrum of disease severity and SARS-CoV-2 variant periods. Remdesivir also appears to improve time to clinical recovery, increase rate of recovery, and reduce time on supplemental oxygen and readmission rates. More recent large, real-world studies further support the early use of remdesivir in a range of patient populations, including those with immunocompromising conditions.
Keywords: Antiviral therapy; COVID-19; Clinical practice guidelines; Real-world evidence; Remdesivir; SARS-CoV-2.